Rare-Disease Biotech Stocks Gain Focus After Protagonist’s $275 Million Milestone and Agios Phase 3 Data
A $275 million Protagonist milestone and Agios’ mixed Phase 3 RISE UP data put rare blood-disease catalysts back in focus.
Novo Nordisk’s CagriSema Delivers 25% Weight Loss in Women as GLP-1 Race Intensifies
CagriSema’s 25% weight-loss result could strengthen Novo Nordisk’s growth narrative as competition with Eli Lilly intensifies.
Disc Medicine’s Bitopertin Data Revive FDA Hopes as IRON Stock Surges
Disc Medicine’s bitopertin data delivered a 41.4% biomarker reduction and more pain-free hours, reviving debate over IRON’s FDA prospects.
TriGemX Bio Plans $600 Million SPAC Merger With TCGX
TriGemX Bio plans to enter public markets through a $600 million merger with TCGX, adding a new biotech name to the US SPAC pipeline.
Disc Medicine Stock Jumps 70% After Positive Phase 3 Bitopertin Results
Disc Medicine’s $IRON surged more than 70% after positive Phase 3 data for bitopertin, putting a potential FDA filing in focus.
Moderna’s Nasdaq-100 Inclusion Tests Investor Confidence in Its Oncology Pivot
Moderna’s Nasdaq-100 inclusion may bring passive-fund demand as Phase 3 melanoma data puts its oncology pivot under closer scrutiny.
Ascendis Pharma Stock Slips Despite Positive European Opinion for Already-Approved YUVIWEL
ASND shares closed down 0.6% after a positive European opinion for YUVIWEL, highlighting how investors distinguish fresh catalysts from pric…
Opus Genetics Wins FDA Approval for Presbyopia Treatment: What IRD Investors Should Watch Next
Opus Genetics received FDA approval for Phentolamine Ophthalmic Solution, creating a potential catalyst as investors assess commercializatio…
Omeros Stock Breaks Key Support After Second EU Rejection of Narsoplimab
Omeros shares fell below key support after the EMA rejected narsoplimab again, highlighting the split between US approval and European setba…
Pfizer's Expanded TUKYSA Approval Strengthens Its Breast Cancer Turnaround Case
TUKYSA’s expanded FDA approval may strengthen Pfizer’s oncology franchise and support its post-pandemic revenue diversification story.
Merck and Moderna’s Phase 3 Cancer Vaccine Win Raises Stakes for mRNA Oncology
Merck and Moderna’s positive Phase 3 cancer-vaccine results strengthen the case for mRNA-immunotherapy combinations and could support future…
Halozyme’s $130 Price Target Reiterated After Positive Takeda Trial Data
H.C. Wainwright reiterated its Buy rating and $130 price target for Nasdaq-listed Halozyme after positive Takeda trial results.











